-
The company Starbucks made a significant business decision a few months ago. Their board decided that they needed to focus on what they thought they did best: Operate as a specialty coffee store.
-
The FDA's amended rule for acceptance of foreign clinical studies not conducted under an investigational new drug (IND) application has drawn fire from health advocates who say it weakens ethical protections.
-
Ethicists and others continue to find it troubling that payments to research participants are part of the recruitment process.
-
From a bioethical perspective, payments to research participants are complicated, an expert says.
-
Every study participant has seen some variation of this assurance in informed consent documents: "You are free to participate in this research or to withdraw at any time without penalty or loss of benefits you are entitled to receive."
-
-
Two or more IRBs reviewing the same study might reach strikingly different conclusions about the study's risks and suitability for human subjects.
-
The growing field of biobanking has added new wrinkles to issues of withdrawal from research. Withdrawing from participation in a biobank or a large cohort study is a very different matter from withdrawing from a clinical trial. Because of the technology involved, it may not be possible to completely remove one's information from the research.
-
The very first step to becoming accredited is to collect all of your institution's policies and procedures related to the human research protection program in a searchable electronic format, an expert advises.
-